AUPH Quote, Financials, Valuation and Earnings

ESSA Pharma has a net margin of 2.39% compared to Aurinia Pharmaceuticals's net margin of --. Aurinia Pharmaceuticals's return on equity of 1.54% beat ESSA Pharma's return on equity of --.

Aurinia Pharmaceuticals has a consensus price target of $9.83, signalling upside risk potential of 21.25%. On the other hand ESSA Pharma has an analysts' consensus of $1.68 which suggests that it could fall by -1.68%. Given that Aurinia Pharmaceuticals has higher upside potential than ESSA Pharma, analysts believe Aurinia Pharmaceuticals is more attractive than ESSA Pharma.

Aurinia Pharmaceuticals has a beta of 1.160, which suggesting that the stock is 16.034% more volatile than S&P 500. In comparison ESSA Pharma has a beta of 1.686, suggesting its more volatile than the S&P 500 by 68.618%.

Aurinia Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ESSA Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aurinia Pharmaceuticals pays -- of its earnings as a dividend. ESSA Pharma pays out -- of its earnings as a dividend.

Aurinia Pharmaceuticals quarterly revenues are $59.9M, which are larger than ESSA Pharma quarterly revenues of --. Aurinia Pharmaceuticals's net income of $1.4M is higher than ESSA Pharma's net income of -$8.5M. Notably, Aurinia Pharmaceuticals's price-to-earnings ratio is 160.50x while ESSA Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aurinia Pharmaceuticals is 4.98x versus -- for ESSA Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience has a net margin of 2.39% compared to Aurinia Pharmaceuticals's net margin of -1559.32%. Aurinia Pharmaceuticals's return on equity of 1.54% beat Lexaria Bioscience's return on equity of -118.15%.

Aurinia Pharmaceuticals has a consensus price target of $9.83, signalling upside risk potential of 21.25%. On the other hand Lexaria Bioscience has an analysts' consensus of $7.00 which suggests that it could grow by 560.38%. Given that Lexaria Bioscience has higher upside potential than Aurinia Pharmaceuticals, analysts believe Lexaria Bioscience is more attractive than Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals has a beta of 1.160, which suggesting that the stock is 16.034% more volatile than S&P 500. In comparison Lexaria Bioscience has a beta of 1.008, suggesting its more volatile than the S&P 500 by 0.806%.

Aurinia Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aurinia Pharmaceuticals pays -- of its earnings as a dividend. Lexaria Bioscience pays out -- of its earnings as a dividend.

Aurinia Pharmaceuticals quarterly revenues are $59.9M, which are larger than Lexaria Bioscience quarterly revenues of $174K. Aurinia Pharmaceuticals's net income of $1.4M is higher than Lexaria Bioscience's net income of -$2.7M. Notably, Aurinia Pharmaceuticals's price-to-earnings ratio is 160.50x while Lexaria Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aurinia Pharmaceuticals is 4.98x versus 32.12x for Lexaria Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

ProMIS Neurosciences has a net margin of 2.39% compared to Aurinia Pharmaceuticals's net margin of --. Aurinia Pharmaceuticals's return on equity of 1.54% beat ProMIS Neurosciences's return on equity of --.

Aurinia Pharmaceuticals has a consensus price target of $9.83, signalling upside risk potential of 21.25%. On the other hand ProMIS Neurosciences has an analysts' consensus of $8.00 which suggests that it could grow by 1499.96%. Given that ProMIS Neurosciences has higher upside potential than Aurinia Pharmaceuticals, analysts believe ProMIS Neurosciences is more attractive than Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals has a beta of 1.160, which suggesting that the stock is 16.034% more volatile than S&P 500. In comparison ProMIS Neurosciences has a beta of 0.016, suggesting its less volatile than the S&P 500 by 98.367%.

Aurinia Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProMIS Neurosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aurinia Pharmaceuticals pays -- of its earnings as a dividend. ProMIS Neurosciences pays out -- of its earnings as a dividend.

Aurinia Pharmaceuticals quarterly revenues are $59.9M, which are larger than ProMIS Neurosciences quarterly revenues of --. Aurinia Pharmaceuticals's net income of $1.4M is lower than ProMIS Neurosciences's net income of $9.3M. Notably, Aurinia Pharmaceuticals's price-to-earnings ratio is 160.50x while ProMIS Neurosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aurinia Pharmaceuticals is 4.98x versus -- for ProMIS Neurosciences. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals has a net margin of 2.39% compared to Aurinia Pharmaceuticals's net margin of --. Aurinia Pharmaceuticals's return on equity of 1.54% beat Xenon Pharmaceuticals's return on equity of --.

Aurinia Pharmaceuticals has a consensus price target of $9.83, signalling upside risk potential of 21.25%. On the other hand Xenon Pharmaceuticals has an analysts' consensus of $57.18 which suggests that it could grow by 60.88%. Given that Xenon Pharmaceuticals has higher upside potential than Aurinia Pharmaceuticals, analysts believe Xenon Pharmaceuticals is more attractive than Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals has a beta of 1.160, which suggesting that the stock is 16.034% more volatile than S&P 500. In comparison Xenon Pharmaceuticals has a beta of 1.212, suggesting its more volatile than the S&P 500 by 21.174%.

Aurinia Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aurinia Pharmaceuticals pays -- of its earnings as a dividend. Xenon Pharmaceuticals pays out -- of its earnings as a dividend.

Aurinia Pharmaceuticals quarterly revenues are $59.9M, which are larger than Xenon Pharmaceuticals quarterly revenues of --. Aurinia Pharmaceuticals's net income of $1.4M is higher than Xenon Pharmaceuticals's net income of -$65.7M. Notably, Aurinia Pharmaceuticals's price-to-earnings ratio is 160.50x while Xenon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aurinia Pharmaceuticals is 4.98x versus 210.19x for Xenon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.